The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial (Publication with Expression of Concern. See vol. 127, pg. 155, 2022)
The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial (Publication with Expression of Concern. See vol. 127, pg. 155, 2022)
复制标题
DOI：
10.1017/s0007114516003251
复制
发表时间：
2016-10-01
影响因子：
3.6
通讯作者：
Asemi, Zatollah
中科院分区：
文献类型：
--
作者：
Bahmani, Fereshteh;Kia, Mahsa;Asemi, Zatollah
本研究旨在评估补硒对糖尿病肾病（DN）患者炎症和氧化应激生物标志物的影响。这项随机、双盲、安慰剂对照的临床试验在60例DN患者中进行。将患者随机分为两组，分别服用酵母硒（n 30）和安慰剂硒（n 30）200 μ g/d，疗程12周。在未校正的分析中，与安慰剂相比，补硒导致高敏C反应蛋白（hs-CRP）显著降低（-1069.2（SD 1752.2）v. -135.3（SD 1258.9）ng/ml，P = 0.02），基质金属蛋白酶-2（MMP-2）（-612.3（SD 679.6）v. + 76.0（SD 309.1）ng/ml，P < 0.001）和血浆丙二醛（MDA）浓度（-0.1（SD 0.7）v.+0.4（SD 0.9）μ mol/l，P = 0.01）。此外，血浆总抗氧化能力（TAC）（+ 174。9（SD 203 . 9)五.+15.第382章. 2)mmol/l，P = 0 . 04)与安慰剂相比，补充硒后观察到。与安慰剂相比，接受硒补充剂的受试者血清蛋白羰基（PCO）水平出现了边缘统计学显著性下降（P = 0.06）。当我们调整了生化参数、年龄和BMI的基线值后，血清hs-CRP（P = 0.14）和MDA（P = 0.16）水平变得无统计学意义，而血浆一氧化氮（NO）（P = 0.04）和谷胱甘肽（GSH）（P < 0.001）变得有统计学意义，其他结果没有变化。与安慰剂相比，补充硒对NO、转化生长因子β（TGF-β）、晚期糖基化终产物（AGE）、PCO和GSH无显著影响。总体而言，我们的研究表明，在DN患者中补充硒对血清MMP-2、血浆NO、TAC和GSH有有利的影响，但对hs-CRP、TGF-β、AGE、PCO和MDA没有影响。
This study was carried out to assess the effects of Se supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy (DN). This randomised, double-blind, placebo-controlled clinical trial was conducted among sixty patients with DN. Patients were randomly divided into two groups to take either 200 mu g/d Se supplements as Se yeast (n 30) or placebo (n 30) for 12 weeks. In unadjusted analyses, compared with the placebo, Se supplementation led to a significant reduction in high-sensitivity C-reactive protein (hs-CRP) (-1069.2 (SD 1752.2) v. -135.3 (SD 1258.9) ng/ml, P = 0.02), matrix metalloproteinase-2 (MMP-2) (-612.3 (SD 679.6) v. + 76.0 (SD 309.1) ng/ml, P < 0.001) and plasma malondialdehyde (MDA) concentrations (-0.1 (SD 0.7) v. +0.4 (SD 0.9) mu mol/l, P = 0.01). In addition, a significant increase in plasma total antioxidant capacity (TAC) (+ 174 . 9 (SD 203 . 9) v. + 15 . 8 (SD 382 . 2) mmol/l, P = 0 . 04) was observed following supplementation with Se compared with the placebo. Subjects who received Se supplements experienced a borderline statistically significant decrease in serum protein carbonyl (PCO) levels (P = 0.06) compared with the placebo. When we adjusted the analysis for baseline values of biochemical parameters, age and BMI, serum hs-CRP (P = 0.14) and MDA levels (P = 0.16) became non-significant, whereas plasma nitric oxide (NO) (P = 0.04) and glutathione (GSH) (P < 0.001) became statistically significant, and other findings did not change. Supplementation with Se had no significant effect on NO, transforming growth factor beta (TGF-beta), advanced glycation end products (AGE), PCO and GSH compared with the placebo. Overall, our study demonstrated that Se supplementation among DN patients had favourable effects on serum MMP-2, plasma NO, TAC and GSH, but did not affect hs-CRP, TGF-beta, AGE, PCO and MDA.